• BridgeBio Pharma set up an at-the-market equity offering program for up to USD 500 million of common stock through Goldman Sachs and Leerink Partners.
• Sales may be made from time to time at company discretion under a shelf registration statement filed May 7, 2026.
• Sales agents will market shares on a best-efforts basis; commissions set at up to 3% of gross proceeds.
• Company terminated its prior May 4, 2023 equity distribution agreement with Goldman Sachs and Leerink Partners, effective May 7, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BridgeBio Pharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001140361-26-019761), on May 08, 2026, and is solely responsible for the information contained therein.